

ACCEPTED VERSION

Luke E. Grzeskowiak, Lisa H. Amir

Use of domperidone to increase breast milk supply: further consideration of the benefit-risk ratio is required

A Journal of Human Lactation, 2015; 31(2):315-316

© The Author(s) 2015

Reprinted by permission of SAGE Publications.

Published version available via DOI: <http://dx.doi.org/10.1177/0890334414567895>

PERMISSIONS

<https://au.sagepub.com/en-gb/occe/journal-author-archiving-policies-and-re-use>

Most SAGE journals are published under SAGE's Green Open Access policy, which allows you, as author, to re-use your Contribution as indicated below. For a list of titles that are exceptions to this policy, please scroll down to the bottom of the page.

Green Open Access policy:

Version 2 original submission to the journal with your revisions after peer review, often the version accepted by the editor (author accepted manuscript)

Version 3 copy-edited and typeset proofs and the final published version

- Once the Contribution has been accepted for publication, you may post the accepted version (**version 2**) of the Contribution on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version (**version 2**) of the Contribution in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject repository) until 12 months after first publication of the Contribution in the journal.

When posting or reusing your Contribution under this policy, appropriate credit must be given to the SAGE journal where the Contribution has been published, as the original source of the content, as follows: **Author(s), Article Title, Journal Title (Journal Volume Number and Issue Number) pp. xx-xx. Copyright © [year] (Copyright Holder). Reprinted by permission of SAGE Publications.** Additionally, please provide a link to the appropriate DOI for the published version of the Contribution on the SAGE Journals website (<http://journals.sagepub.com>).

14 March 2018

<http://hdl.handle.net/2440/97123>

Use of domperidone to increase breast milk supply: further consideration of the benefit-risk ratio is required

Luke E Grzeskowiak, Lisa H Amir

Luke E Grzeskowiak, PhD, BPharm (Hons), GCertClinEpid, FSHP

1. School of Paediatrics and Reproductive Health, The Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia

E-mail: Luke.Grzeskowiak@adelaide.edu.au

Lisa H Amir, PhD, MBBS, MMed

1. Judith Lumley Centre, La Trobe University, Melbourne, Victoria, Australia
2. Breastfeeding Service, Royal Women's Hospital, Melbourne, Victoria, Australia

E-mail: L.amir@latrobe.edu.au

Corresponding Author:

Luke Grzeskowiak

The Robinson Research Institute, The University of Adelaide

Lyell McEwin Hospital

Haydown Road

Elizabeth Vale, 5112

South Australia, Australia

T: +61 8 8133 2133

F: +61 8 8182 9337

E-mail: Luke.Grzeskowiak@adelaide.edu.au

Word Count:

Main Text: 470

Key Words: Domperidone; Galactagogue; lactation; breastfeeding; insufficient milk supply

Declaration of Conflicting Interests

The author declares no conflicts of interest

Use of domperidone to increase breast milk supply: further consideration of the benefit-risk ratio is required

The statement made by Paul *et al.* in their systematic review, that “the use of domperidone as a galactagogue is worrisome as drug-induced long QT syndrome occurred mostly in women”¹, is extremely misleading and not reflective of current evidence. To be clear, there is no evidence that the risk of QT interval prolongation associated with the use of domperidone is higher among females.^{2,3} Not discussed by Paul *et al.* are the results of a recent case-control study investigating the risk of serious ventricular arrhythmia and sudden cardiac death associated with the use of domperidone, in which an increased risk was only observed among males (adjusted Odds Ratio [aOR] 2.23; 95% Confidence Interval [CI] 1.59, 3.13), but not females (aOR 1.25; 95% CI 0.93, 1.67).⁴ Furthermore, an increased risk was only observed among those > 60 years of age (aOR 1.64; 95% CI 1.31, 2.05), and not among those ≤ 60 years of age (aOR 1.1; 95% CI 0.35-3.47).⁴ Also omitted from the review by Paul *et al.*¹ is any discussion of a recent randomised, placebo-controlled, double-blind, crossover study evaluating the impact of domperidone on QT prolongation among healthy volunteers aged 18-39 years (representing the likely cohort of breastfeeding mothers).⁵ In the study of volunteers, domperidone was demonstrated to prolong the QT interval among males, but no difference in QT interval was observed among females.⁵ Taken together, these findings provide evidence of a favourable safety profile of domperidone use in breastfeeding mothers.

In addition the review by Paul *et al.*¹ lacks any consideration of the risks associated with not breastfeeding. It is unclear how the benefit-risk profile of domperidone without considering its role in maintaining breast milk feeding. We also direct the authors towards a recent article investigating the effect of breastfeeding on postpartum depression. In this study, the highest risk of postpartum depression was observed among women who had planned to breastfeed and had not been able to achieve their goal.⁶ The authors stressed the necessity to provide expert breastfeeding support to women who want to breastfeed, but also the importance of providing compassionate support for women who had intended to breastfeed, but who find themselves unable to. This highlights the importance of maintaining access to a medication such as domperidone that can assist with the

management of low milk supply. Despite its use being ‘off-label’, domperidone has a long track record of use in lactating mothers,⁷ with no reports of significant adverse effects. While the use of domperidone should never be considered a magic bullet nor as a substitute for effective non-pharmacological breastfeeding support and encouragement, we strongly feel that it can be used safely and effectively where appropriate.^{2,3} We firmly believe that the misguided interpretation of the current evidence risks subjecting breastfeeding women to the status of therapeutic orphans and causing more harm than good.

Conflict of Interest:

The authors have indicated that they have no financial relationships or conflicts of interest relevant to this article to disclose.

References

1. Paul C, Zénut M, Dorut A, et al. Use of Domperidone as a Galactagogue Drug A Systematic Review of the Benefit-Risk Ratio. *Journal of Human Lactation*. 2014;0890334414561265.
2. Grzeskowiak L. Use of Domperidone to Increase Breast Milk Supply: Are Women Really Dying to Breastfeed? *Journal of Human Lactation*. 2014;30(4):498-499.
3. Grzeskowiak LE, Amir LH. Pharmacological management of low milk supply with domperidone: separating fact from fiction. *Medical Journal of Australia*. 2014;201(5):257-258.
4. Johannes CB, Varas-Lorenzo C, McQuay LJ, Midkiff KD, Fife D. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. *Pharmacoepidemiol Drug Saf*. 2010;19(9):881-888.
5. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. *British journal of clinical pharmacology*. 2012;73(3):411-421.
6. Borra C, Iacovou M, Sevilla A. New Evidence on Breastfeeding and Postpartum Depression: The Importance of Understanding Women's Intentions. *Maternal and child health journal*. 2014:1-11.
7. Grzeskowiak LE, Lim SW, Thomas AE, Ritchie U, Gordon AL. Audit of Domperidone Use as a Galactagogue at an Australian Tertiary Teaching Hospital. *Journal of Human Lactation*. 2013;29(1):32-37.